Natera Inc (NTRA) Receives $29.00 Average Target Price from Analysts
Natera Inc (NASDAQ:NTRA) has received a consensus rating of “Buy” from the eleven analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $29.00.
Several equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Tuesday, January 22nd. ValuEngine raised shares of Natera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 15th. BidaskClub cut shares of Natera from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 15th. Finally, Cowen reaffirmed a “buy” rating and issued a $30.00 price target on shares of Natera in a research report on Friday, November 9th.
A number of large investors have recently bought and sold shares of NTRA. Citigroup Inc. increased its stake in shares of Natera by 930.0% during the 4th quarter. Citigroup Inc. now owns 193,618 shares of the medical research company’s stock worth $2,703,000 after purchasing an additional 174,821 shares during the last quarter. Prescott Group Capital Management L.L.C. increased its stake in shares of Natera by 18.6% during the 4th quarter. Prescott Group Capital Management L.L.C. now owns 147,628 shares of the medical research company’s stock worth $2,061,000 after purchasing an additional 23,200 shares during the last quarter. First Trust Advisors LP purchased a new stake in shares of Natera during the 4th quarter worth approximately $2,813,000. Jennison Associates LLC increased its stake in shares of Natera by 1.8% during the 4th quarter. Jennison Associates LLC now owns 3,706,873 shares of the medical research company’s stock worth $51,748,000 after purchasing an additional 65,025 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Natera during the 4th quarter worth approximately $1,311,000. Hedge funds and other institutional investors own 87.50% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Find a Trading Strategy That Works
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.